This study is testing a medicine called efruxifermin (EFX) in people with liver problems called non-cirrhotic NASH/MASH and fibrosis. NASH/MASH is a type of liver disease caused by fat build-up, not alcohol. Fibrosis means scar tissue in the liver. People in the study will be randomly given either EFX or a fake treatment called a placebo. The study will not tell participants which one they receive (this is called double-blind). The study includes 1650 people at different places (multi-center).
Key Points:
- Eligibility: You must be 18-80 years old, have certain health conditions like obesity or diabetes, and meet specific liver test requirements.
- Commitment: You need a recent liver biopsy. The study length and number of visits will be determined by the study team.
- Risks: There are potential risks, like the placebo might not help your condition, and there might be side effects from EFX.
If you have other liver diseases or severe diabetes, you may not join. It's important to discuss with your doctor if you're interested in participating.
How understandable was the trial content above?
Hard to understand
Easy to understand